PHASE-II STUDY OF 4'-EPI-DOXORUBICIN IN METASTATIC RENAL-CANCER

Abstract

In 20 patients with measurable metastatic renal cancer, 4''-epi-doxorubicin (adriamycin) administration (75 mg/m2, every 3 wk) did not result in any tumor remission. Hematologic and gastrointestinal toxicity was generally mild to moderate. Anthracycline-induced cardiac side effects were not observed in any of the patients.